The Indian Supreme Court has failed to provide the clarity which is craved by practitioners in its latest pronouncement on the controversial Section 3(d), says Jitesh Kumar.
Many of the world’s biggest selling drugs have lost exclusivity in recent years, presenting huge opportunities for generic drugs companies but, as LSIPR finds out, it doesn’t have to be a dead end for the innovators.
For generic drug makers, previous bad behaviour may affect new litigation, especially when it comes to injunctions, as Bethan Hopewell and Geraldine Quinn explain.
The law of patents and SPCs has yet to be tested in the context of medicines which can be used to treat specific groups of patients, as Paul England explains.
While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges.
To read much of the reaction to recent pharmaceutical rulings in India, you might think that the country is waging a war against Western innovation. But while there is certainly cause for concern, that’s not the whole story, as LSIPR finds out.
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.
While no court has tested it, Brazilian legislation seems to prohibit pay-for-delay settlements in the pharmaceutical industry. Gabriel Di Blasi argues that it’s time for a test case.
Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate.
While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.